Clinical trials for Prostate specific antigen test

The European Union Clinical Trials Register allows you to search for protocol and results information on:

interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC

clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
Clinical Trials Information System (CTIS).

The EU Clinical Trials Register currently displays 44339 clinical trials with a EudraCT protocol, of which 7369 are clinical trials conducted with subjects less than 18 years old. The register also displays information on 18700 older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).

Examples: Cancer AND drug name. Pneumonia AND sponsor name.
How to search [pdf]

Advanced Search:

Search tools

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Trials with a EudraCT protocol (189)
Paediatric studies in scope of Art45 of the Paediatric Regulation (0)

189 result(s) found for: Prostate specific antigen test. Displaying page 8 of 10.

EudraCT Number: 2021-000248-23

Sponsor Protocol Number: C3441052

Start Date*: 2021-10-22

Sponsor Name:Pfizer Inc.

Full Title: TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER

Medical condition: Metastatic Castration-sensitive Prostate Cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10036909	Prostate cancer metastatic	PT

Population Age: Adults, Elderly

Gender: Male

Trial protocol: CZ (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) NO (Trial now transitioned) SK (Trial now transitioned) FI (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) BG (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2005-005255-18	Sponsor Protocol Number: 1216.19	Start Date*: 2006-07-03
Sponsor Name:Boehringer Ingelheim UK Ltd
Full Title: A single arm phase II study to investigate the efficacy, safety and pharmacokinetics of a single dose of 200 mg of i.v. BI 2536, administered once every 3 weeks in patients with advanced metastatic...
Medical condition: Advanced Metastatic Hormone Refractory Prostate Cancer
Disease:
Population Age: Adults		Gender: Male
Trial protocol: GB (Completed)
Trial results: View results

EudraCT Number: 2018-004117-40

Sponsor Protocol Number: MK-3475-641

Start Date*: 2020-03-05

Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Full Title: A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) ...

Medical condition: Metastatic Castration-Resistant Prostate Cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10036909	Prostate cancer metastatic	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10076506	Castration-resistant prostate cancer	LLT

Population Age: Adults, Elderly

Gender: Male

Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) AT (Trial now transitioned) GB (GB - no longer in EU/EEA) PL (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) IE (Trial now transitioned) IT (Trial now transitioned) CZ (Ongoing) HU (Trial now transitioned) BG (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2015-004314-15

Sponsor Protocol Number: SP015

Start Date*: 2016-11-16

Sponsor Name:SOTIO a.s.

Full Title: A phase I/II, single-arm clinical trial to evaluate the safety and immune activation of the combination of DCVAC/PCa, an active cellular immunotherapy, and ONCOS-102, an immune-priming adenovirus, ...

Medical condition: advanced metastatic castration-resistant prostate cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10036909	Prostate cancer metastatic	PT

Population Age: Adults, Elderly

Gender: Male

Trial protocol: CZ (Completed)

Trial results: View results

EudraCT Number: 2017-003552-23

Sponsor Protocol Number: 64091742PCR2002

Start Date*: 2018-05-10

Sponsor Name:Janssen-Cilag International NV

Full Title: A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Medical condition: Metastatic castration-resistant prostate cancer (mCRPC)

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10076506	Castration-resistant prostate cancer	LLT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10036909	Prostate cancer metastatic	PT

Population Age: Adults, Elderly

Gender: Male

Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) BE (Completed) IT (Completed)

Trial results: (No results available)

EudraCT Number: 2016-001179-60	Sponsor Protocol Number: CABASTY	Start Date*: 2019-10-21
Sponsor Name:A.R.T.I.C (Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie)
Full Title: Randomized multicenter, phase III trial evaluating the safety of 2 schedules of cabazitaxel (bi-weekly versus tri-weekly) plus prednisone in elderly men (≥ 70 years) with metastatic castration-resi...
Medical condition: Metastatic castration-resistant prostate cancer (mCRPC)
Disease:
Population Age: Elderly		Gender: Male
Trial protocol: NL (Completed) DE (Completed)
Trial results: (No results available)

EudraCT Number: 2012-004866-16

Sponsor Protocol Number: I5E-MC-TSAT

Start Date*: 2013-06-06

Sponsor Name:Eli Lilly and Company

Full Title: A Randomized, Double-Blind, Placebo-Controlled Parallel Study with an Open-Label Extension to Assess the Impact of Testosterone Solution on Total Testosterone, Sex Drive and Energy in Hypogonadal Men.

Medical condition: Male hypogonadism

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.1	10014698 - Endocrine disorders	10021011	Hypogonadism male	PT

Population Age: Adults, Elderly

Gender: Male

Trial protocol: DE (Completed) IT (Completed) GB (Completed) ES (Completed)

Trial results: View results

EudraCT Number: 2020-003969-19

Sponsor Protocol Number: CAAA617B12302

Start Date*: 2021-05-28

Sponsor Name:Novartis Pharma AG

Full Title: PSMAfore : A phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of androgen receptor-directed therapy in the Treatment of Taxane Naïve Men with Progressive ...

Medical condition: PSMA-positive metastatic castration-resistant prostate cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.1	100000004864	10076506	Castration-resistant prostate cancer	LLT

Population Age: Adults, Elderly

Gender: Male

Trial protocol: SK (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) CZ (Trial now transitioned) SE (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2017-004034-29

Sponsor Protocol Number: A206T-G01-001

Start Date*: 2018-12-19

Sponsor Name:Advanced Accelerator Applications International SA

Full Title: A Phase I/II open-label, multi-center, dose-escalation study of safety, tolerability, pharmacokinetics, dosimetry, and response to repeat dosing of 177Lu-PSMA-R2 radio-ligand therapy in patients wi...

Medical condition: Patients with PSMA positive Metastatic Castration-resistant Prostate Cancer (mCRPC), and disease progression following previous systemic treatment for mCRPC.

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	100000004864	10036908	Prostatic neoplasms malignant	HLT

Population Age: Adults, Elderly

Gender: Male

Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended)

Trial results: View results

EudraCT Number: 2021-001789-39

Sponsor Protocol Number: LAVA1207-001

Start Date*: 2021-07-13

Sponsor Name:LAVA Therapeutics N.V.

Full Title: A Phase 1 and 2a open-label trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of LAVA-1207, a PSMA-targeting bispecific γδ-T cel...

Medical condition: Prostate Cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	27.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10036909	Prostate cancer metastatic	PT

Population Age: Adults, Elderly

Gender: Male

Trial protocol: NL (Trial now transitioned) ES (Ongoing)

Trial results: (No results available)

EudraCT Number: 2021-001917-35	Sponsor Protocol Number: NOX66-005	Start Date*: 2021-10-25
Sponsor Name:Noxopharm Limited
Full Title: A Phase 1b/2a Multicenter Study of NOX66 and External Beam Radiotherapy in Patients with Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors
Medical condition: Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: HU (Completed)
Trial results: View results

EudraCT Number: 2017-003287-12

Sponsor Protocol Number: CORT125281-601

Start Date*: 2018-02-08

Sponsor Name:Corcept Therapeutics Incorporated

Full Title: Phase 1/2a dose-escalation and expansion study to evaluate the safety, tolerability and pharmacokinetics of CORT125281 with enzalutamide in patients with metastatic castration-resistant prostate ca...

Medical condition: Metastatic castration-resistant prostate cancer.

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.1	100000004864	10076506	Castration-resistant prostate cancer	LLT

Population Age: Adults, Elderly

Gender: Male

Trial protocol: GB (GB - no longer in EU/EEA)

Trial results: (No results available)

EudraCT Number: 2015-001361-27

Sponsor Protocol Number: ICR-CTSU/2015/10054

Start Date*: 2016-09-21

Sponsor Name:The Institute of Cancer Research

Full Title: CTC-STOP: Utilising Circulating Tumour Cell (CTC) Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer.

Medical condition: Advanced Castration Resistant Prostate Cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.0	100000004864	10001198	Adenocarcinoma of the prostate metastatic	LLT

Population Age: Adults, Elderly

Gender: Male

Trial protocol: GB (Prematurely Ended)

Trial results: View results

EudraCT Number: 2016-004334-17

Sponsor Protocol Number: EORTC-1532-GUCG

Start Date*: 2017-09-21

Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)

Full Title: A phase 2 Randomized Open-Label Study of Oral darolutamide (ODM-201) vs. androgen deprivation therapy (ADT) with LHRH agonists or antagonist in Men with Hormone Naive Prostate Cancer

Medical condition: Hormone Naive Prostate Cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10071119	Hormone-dependent prostate cancer	PT

Population Age: Adults, Elderly

Gender: Male

Trial protocol: BE (Trial now transitioned) AT (Completed) ES (Ongoing) IT (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2018-004365-13	Sponsor Protocol Number: CTOR18001GZA	Start Date*: 2019-02-04
Sponsor Name:GZA vzw
Full Title: A phase II randomized, open-label study comparing salvage radiotherapy in combination with 6 months of androgen-deprivation therapy (ADT) with LHRH agonist or antagonist versus anti-adrogen therapy...
Medical condition: Prostate cancer patients with biochemical progression after radical prostatectomy and planned for salvage radiotherapy
Disease:
Population Age: Adults, Elderly		Gender: Male
Trial protocol: BE (Trial now transitioned)
Trial results: (No results available)

EudraCT Number: 2010-023062-40

Sponsor Protocol Number: PRP-001

Start Date*: 2011-04-19

Sponsor Name:Medivation, Inc.

Full Title: A Phase 1/2, First in Human, Single-arm, Open-label Study of Once a Day, Orally Administered Talazoparib (BMN 673) in Patients with Advanced or Recurrent Solid Tumors

Medical condition: Advanced or recurrent solid tumors for which there is no accepted standard treatment or for which standard treatment has failed. Patients may also be eligible if they are unable or decline to unde...

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	19.0	100000004864	10065147	Malignant solid tumor	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (Completed)

Trial results: View results

EudraCT Number: 2019-003792-19	Sponsor Protocol Number: FOS-PROST-001	Start Date*: 2021-03-04
Sponsor Name:Hospital Universitari Mutua Terrassa
Full Title: Fosfomycin as an oral alternative treatment for acute bacterial prostatitis due to multi-drug resistant Escherichia coli. Pilot study
Medical condition: Acute bacterial prostatitis due to multi-drug resistant Escherichia coli
Disease:
Population Age: Adults, Elderly		Gender: Male
Trial protocol: ES (Ongoing)
Trial results: (No results available)

EudraCT Number: 2022-000066-18	Sponsor Protocol Number: S65935	Start Date*: 2022-03-23
Sponsor Name:Universitaire Ziekenhuizen Leuven
Full Title: Metastasis-directed therapy for oligorecurrent prostate cancer: a randomized phase III trial
Medical condition: Oligorecurrent hormone-sensitive prostate cancer patients
Disease:
Population Age: Adults, Elderly		Gender: Male
Trial protocol: BE (Trial now transitioned)
Trial results: (No results available)

EudraCT Number: 2018-004118-16

Sponsor Protocol Number: MK-7339-010

Start Date*: 2019-04-15

Sponsor Name:Merck Sharp & Dohme LLC

Full Title: A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castrationresistant Prostate Cancer (mCRPC...

Medical condition: Metastatic Castration resistant Prostate Cancer (mCRPC)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.1	100000004864	10076506	Castration-resistant prostate cancer	LLT

Population Age: Adults, Elderly

Gender: Male

Trial protocol: NL (Completed) GB (GB - no longer in EU/EEA) FR (Completed) ES (Completed) IE (Completed) IT (Completed)

Trial results: View results

EudraCT Number: 2007-003470-26	Sponsor Protocol Number: 07TASQ08	Start Date*: 2007-10-17
Sponsor Name:Active Biotech Research AB
Full Title: Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients with Metastatic Castrate-Resistant Prostate Cancer. Final Protocol dated 2...
Medical condition: Prostate cancer
Disease:
Population Age: Adults, Elderly		Gender: Male
Trial protocol: SE (Completed)
Trial results: View results

Subscribe to this Search
To subscribe to the RSS feed for this search click here

. This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.

Download Options:
Number of Trials to download:

Download Content:

Download Format:


Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.

Query did not match any studies.

For support, Contact us.

The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

European Medicines Agency © 1995-Fri May 30 06:35:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA